Compare Dolby Laboratories, Inc. (DLB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Sana Biotechnology Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.93 (market cap $5.75B), while Sana Biotechnology Inc trades at $3.73 (market cap $1.13B). The key difference: Dolby Laboratories, Inc. is far larger — about 5.1× Sana Biotechnology Inc's market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DLB | SANA | |
|---|---|---|
Market Cap | $5.75B | $1.13B |
Sector | Industrials | Health |
52-Week High | $75.62 | $5.92 |
52-Week Low | $48.51 | $2.68 |
Enterprise Value | $5.12B | $1.05B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $60.74, down 2.19% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with an 87.61% gross margin and has beaten EPS estimates for four consecutive quarters. Recent news highlights innovation in automotive and broadcast licensing, though revenue growth remains choppy.
The stock presents a compelling opportunity with a consensus price target of $87.50, implying significant upside, but faces near-term execution risks and licensing volatility. Long-term growth drivers in premium audio/visual formats are balanced by macroeconomic sensitivity and competitive pressures.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
